ArticleArthroplasty (London, England)2026
Calprotectin identified as a key differentially expressed plasma biomarker in periprosthetic joint infection against aseptic failure: a precision health proteomics study.
Article in Arthroplasty (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPeriprosthetic joint infection (PJI) is a debilitating and dangerous complication following joint arthroplasty procedures. With the increasing incidence of arthroplasty procedures, the burden of PJI is expected to continually grow. A correct and early diagnosis of PJI proves difficult, with the lack of a single standardized molecular test. The utilization of serology-based biomarkers would provide a non-invasive sampling method; however, these methods have not proven sufficient to satisfy the diagnostic criteria.
methodsThe present study aimed to employ liquid chromatography/mass spectrometry-based (LC-MS) techniques to explore the proteomic profile of plasma samples derived from a prospective Danish PJI cohort, PRIS, to identify relevant proteins that are significantly differentially expressed in acute PJI compared to those with aseptic failure or chronic pain related to the prosthesis. Serum from patients included in the LC-MS analysis was measured for a biomarker of neutrophil activity, CPa9-HNE, measuring a neo-epitope of neutrophil elastase-cleaved calprotectin.
resultsA total of 656 plasma proteins were quantified by the discovery proteomic approach, and differential abundance analysis showed increased abundance of calprotectin heterodimers, S100A8, and S100A9 in acute PJI samples compared to both aseptic failure and chronic pain. Functional enrichment of the significantly regulated proteins in acute PJI, compared to aseptic failure and chronic pain, showed an upregulation of acute immune-related pathways. Serum levels of a biomarker of neutrophil activity, an elastase-derived calprotectin neo-epitope, CPa9-HNE, showed statistically significant differences between infection and both aseptic failure and chronic pain in the same cohort, supporting the findings in LC-MS analysis.
conclusionPlasma LC-MS proteomics and targeted measurement of CPa9-HNE neutrophil activity biomarker in matched serum samples of patients with PJI, aseptic failure, and chronic pain show significant upregulation of calprotectin heterodimers, S100A8 and S100A9, as well as CPa9-HNE in patients with PJI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.